Zhang Tao, Zhai Min, Ji Jianbo, Zhang Jian, Tian Ye, Liu Xinyong
Department of Medicinal Chemisry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, Jinan 255012, China; Shandong Qidu Pharmaceutical Co. Ltd., Shandong Provincial Key Laboratory of Neuroprotective Drugs, Zibo 255400, China.
Shandong Qidu Pharmaceutical Co. Ltd., Shandong Provincial Key Laboratory of Neuroprotective Drugs, Zibo 255400, China.
Bioorg Med Chem Lett. 2017 Jun 1;27(11):2364-2368. doi: 10.1016/j.bmcl.2017.04.028. Epub 2017 Apr 12.
Ebola virus is one of the most threatening pathogens with the mortality rate as high as 90% in the world. There are no licensed therapeutic drugs or preventive vaccines for Ebola hemorrhagic fever up to date. Favipiravir, a novel antiviral drug which was mainly used for the treatment of influenza, now has been demonstrated to have a curative effect in treating Ebola virus infection. In this review, we present an overview of recent progress on the treatment of Ebola virus disease with Favipiravir and describe its possible mechanism. Moreover, we give a brief summary of other related treatment strategies against Ebola.
埃博拉病毒是世界上最具威胁的病原体之一,死亡率高达90%。迄今为止,尚无用于治疗埃博拉出血热的获批治疗药物或预防性疫苗。法匹拉韦是一种主要用于治疗流感的新型抗病毒药物,现已证明对治疗埃博拉病毒感染有疗效。在这篇综述中,我们概述了法匹拉韦治疗埃博拉病毒病的最新进展,并描述了其可能的作用机制。此外,我们简要总结了其他针对埃博拉的相关治疗策略。